Recent advances in therapy of chronic lymphocytic leukaemia
Author:
Affiliation:
1. Department of Haematology; The Christie NHS Foundation Trust; Manchester UK
2. University of Manchester; Manchester UK
3. Manchester Academic Health Science Centre; Manchester UK
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14184/fullpdf
Reference97 articles.
1. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies;Agathangelidis;Blood,2012
2. B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292;Arnason;ImmunoTargets and Therapy,2014
3. Long-term follow-up of a phase 1 trial of Idelalisib (ZYDELIG®) in combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL);Barrientos;Blood,2014
4. Outcomes of patients with chronic lymphocytic leukemia (CLL) after idelalisib therapy discontinuation;Barrientos;Blood,2015
5. Survival of leukemic B cells promoted by engagement of the antigen receptor;Bernal;Blood,2001
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines;Leukemia Research;2021-10
2. The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia;2021-03-24
3. The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia;OncoImmunology;2021-01-01
4. Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab‑associated anaphylaxis;Polish Archives of Internal Medicine;2018-08-31
5. Ailanthone induces autophagic and apoptotic cell death in human promyelocytic leukemia HL‑60 cells;Oncology Letters;2018-07-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3